A major purpose of Multiply Labs' consortium is to reduce the time and cost associated with the manual labor demands linked with cell therapy manufacturing. By automating these processes with robotic technologies and innovations, the consortium supports more efficient generation of cell therapies to provide patients with access to them sooner. As a result, the consortium demonstrates the beneficial capabilities of robotic integration into the drug manufacturing process.

Multiply Labs coordinates activities in the consortium related to robotics development, while UCSF is tasked with leading the cell manufacturing process as part of a research agreement. Regarding the roles of other consortium members, Cytiva uses its specialized bioreactor technology to manufacture CAR T-cell therapies. As new additions, Thermo Fisher will guide the automated operation of incubators and Charles River will focus on automating the quality control testing required as part of the manufacturing process. These institutions will all work toward the common goal of bringing these gene modified cell therapies to patients more quickly with the advantage of robotic technology.